KR20210143255A - 갈렉틴-3의 소분자 억제제 - Google Patents
갈렉틴-3의 소분자 억제제 Download PDFInfo
- Publication number
- KR20210143255A KR20210143255A KR1020217034150A KR20217034150A KR20210143255A KR 20210143255 A KR20210143255 A KR 20210143255A KR 1020217034150 A KR1020217034150 A KR 1020217034150A KR 20217034150 A KR20217034150 A KR 20217034150A KR 20210143255 A KR20210143255 A KR 20210143255A
- Authority
- KR
- South Korea
- Prior art keywords
- independently
- mmol
- och
- alkyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*C(N1[Al]*)=NNC1=S Chemical compound C*C(N1[Al]*)=NNC1=S 0.000 description 4
- FBZVZUSVGKOWHG-UHFFFAOYSA-N CC(N(C)C)(OC)OC Chemical compound CC(N(C)C)(OC)OC FBZVZUSVGKOWHG-UHFFFAOYSA-N 0.000 description 1
- PREKIMKSEQJHMU-ZTLRGGAMSA-N CC(N([C@H]([C@H]1OC(C)=O)[C@H]2O[C@@H](c3ccccc3)OC[C@H]2O[C@H]1C(OC)=O)N=N)Cl Chemical compound CC(N([C@H]([C@H]1OC(C)=O)[C@H]2O[C@@H](c3ccccc3)OC[C@H]2O[C@H]1C(OC)=O)N=N)Cl PREKIMKSEQJHMU-ZTLRGGAMSA-N 0.000 description 1
- YKPQTNNELFORFG-GEIYBXPISA-N CC([C@@H](C)Cl)N([C@H]([C@H]1O)[C@H]2O[C@@H](c3ccccc3)OC[C@H]2O[C@H]1C(N)=O)/N=N\C Chemical compound CC([C@@H](C)Cl)N([C@H]([C@H]1O)[C@H]2O[C@@H](c3ccccc3)OC[C@H]2O[C@H]1C(N)=O)/N=N\C YKPQTNNELFORFG-GEIYBXPISA-N 0.000 description 1
- NWCYIFOZQJOJMW-UHFFFAOYSA-N C[Si](C)(C)C#Cc(cc1F)cc(F)c1Cl Chemical compound C[Si](C)(C)C#Cc(cc1F)cc(F)c1Cl NWCYIFOZQJOJMW-UHFFFAOYSA-N 0.000 description 1
- SWELJVAWQMCJLG-UHFFFAOYSA-N Fc1cc(Br)cc(F)c1Cl Chemical compound Fc1cc(Br)cc(F)c1Cl SWELJVAWQMCJLG-UHFFFAOYSA-N 0.000 description 1
- ZTUJPDAKWRWBMX-UHFFFAOYSA-N NNc1cc(Cl)ccc1C(F)(F)F Chemical compound NNc1cc(Cl)ccc1C(F)(F)F ZTUJPDAKWRWBMX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962823684P | 2019-03-26 | 2019-03-26 | |
| US62/823,684 | 2019-03-26 | ||
| PCT/US2020/024548 WO2020198266A1 (en) | 2019-03-26 | 2020-03-25 | Small molecule inhibitors of galectin-3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210143255A true KR20210143255A (ko) | 2021-11-26 |
Family
ID=70293127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217034150A Pending KR20210143255A (ko) | 2019-03-26 | 2020-03-25 | 갈렉틴-3의 소분자 억제제 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12275719B2 (https=) |
| EP (1) | EP3947407B1 (https=) |
| JP (1) | JP7478165B2 (https=) |
| KR (1) | KR20210143255A (https=) |
| CN (1) | CN113727988A (https=) |
| ES (1) | ES2984075T3 (https=) |
| WO (1) | WO2020198266A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230104190A (ko) * | 2020-11-02 | 2023-07-07 | 이도르시아 파마슈티컬스 리미티드 | 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체 |
| JP2024501010A (ja) * | 2020-12-28 | 2024-01-10 | ガレクト バイオテック エービー | ガレクチンに対する新規ガラクトシド阻害剤 |
| WO2023118267A1 (en) * | 2021-12-22 | 2023-06-29 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| WO2026002250A1 (zh) * | 2024-06-28 | 2026-01-02 | 上海济煜医药科技股份有限公司 | 四唑基取代的吡喃半乳糖苷衍生物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401301D0 (sv) * | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| US9021050B2 (en) | 2012-08-31 | 2015-04-28 | Yume, Inc. | Network service system and method with off-heap caching |
| US8828971B2 (en) | 2012-10-10 | 2014-09-09 | Galectin Therapeutics, Inc. | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders |
| JP2015535233A (ja) | 2012-10-31 | 2015-12-10 | ガレクト・バイオテック・エイビイ | ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用 |
| JP6904906B2 (ja) * | 2015-01-30 | 2021-07-21 | ガレクト・バイオテック・エイビイ | ガレクチンの新規なガラクトシド阻害剤 |
| JP6844991B2 (ja) | 2015-11-10 | 2021-03-17 | サンコ テキスタイル イスレットメレリ サン ベ ティク エーエスＳａｎｋｏ Ｔｅｋｓｔｉｌ Ｉｓｌｅｔｍｅｌｅｒｉ Ｓａｎ． Ｖｅ Ｔｉｃ． Ａ．Ｓ． | ジッパーを有する伸縮性衣類の製法 |
| CA3025867A1 (en) * | 2016-07-12 | 2018-01-18 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| CA3062648A1 (en) * | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| WO2019067702A1 (en) | 2017-09-27 | 2019-04-04 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
-
2020
- 2020-03-25 EP EP20719877.1A patent/EP3947407B1/en active Active
- 2020-03-25 ES ES20719877T patent/ES2984075T3/es active Active
- 2020-03-25 JP JP2021557333A patent/JP7478165B2/ja active Active
- 2020-03-25 CN CN202080030355.9A patent/CN113727988A/zh active Pending
- 2020-03-25 US US17/439,845 patent/US12275719B2/en active Active
- 2020-03-25 KR KR1020217034150A patent/KR20210143255A/ko active Pending
- 2020-03-25 WO PCT/US2020/024548 patent/WO2020198266A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3947407A1 (en) | 2022-02-09 |
| CN113727988A (zh) | 2021-11-30 |
| US12275719B2 (en) | 2025-04-15 |
| WO2020198266A1 (en) | 2020-10-01 |
| EP3947407B1 (en) | 2024-06-12 |
| US20220185800A1 (en) | 2022-06-16 |
| JP7478165B2 (ja) | 2024-05-02 |
| ES2984075T3 (es) | 2024-10-28 |
| JP2022527075A (ja) | 2022-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022263410B2 (en) | Carboxy-benzimidazole glp-1r modulating compounds | |
| US11267811B2 (en) | Small molecule inhibitors of galectin-3 | |
| US10954214B2 (en) | Pyrazole derivatives as MALT1 inhibitors | |
| KR20210143255A (ko) | 갈렉틴-3의 소분자 억제제 | |
| KR20240127910A (ko) | Sos1 억제제 및 항암제를 포함하는 암 치료용 약학 조성물 | |
| WO2016198374A1 (en) | Aromatic sulfonamide derivatives | |
| KR20210150485A (ko) | 갈렉틴-3의 소분자 억제제 | |
| US11795172B2 (en) | Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors | |
| EP3807290B1 (en) | Tetrahydropyran-based thiodisaccharide mimics as galectin-3 inhibitors | |
| EP2934536B1 (en) | FACTOR IXa INHIBITORS | |
| CN111164084B (zh) | 可用作a2a受体拮抗剂的三唑并三嗪衍生物 | |
| US12275720B2 (en) | Small molecule inhibitors of galectin-3 | |
| EP4157833A1 (en) | Galectin-3 inhibitors | |
| US12275718B2 (en) | Small molecule inhibitors of galectin-3 | |
| EA050465B1 (ru) | Соединения карбокси-бензимидазола, модулирующие glp-1r | |
| HK40019785B (en) | Triazolotriazine derivatives as a2a receptor antagonists | |
| HK40014620A (en) | Pyrazole derivatives as malt1 inhibitors | |
| NZ623098A (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |